* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download (DNA, RNA, or DNA/RNA) Microinjection Service Form
Nucleic acid tertiary structure wikipedia , lookup
Frameshift mutation wikipedia , lookup
Epigenetics wikipedia , lookup
Transposable element wikipedia , lookup
Comparative genomic hybridization wikipedia , lookup
Metagenomics wikipedia , lookup
Epigenetics in learning and memory wikipedia , lookup
DNA profiling wikipedia , lookup
Mitochondrial DNA wikipedia , lookup
Genome evolution wikipedia , lookup
History of RNA biology wikipedia , lookup
DNA polymerase wikipedia , lookup
RNA silencing wikipedia , lookup
Oncogenomics wikipedia , lookup
Human genome wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Cancer epigenetics wikipedia , lookup
Genetic engineering wikipedia , lookup
United Kingdom National DNA Database wikipedia , lookup
SNP genotyping wikipedia , lookup
Genealogical DNA test wikipedia , lookup
Gel electrophoresis of nucleic acids wikipedia , lookup
DNA damage theory of aging wikipedia , lookup
Bisulfite sequencing wikipedia , lookup
Zinc finger nuclease wikipedia , lookup
DNA vaccination wikipedia , lookup
Non-coding RNA wikipedia , lookup
Designer baby wikipedia , lookup
Nucleic acid double helix wikipedia , lookup
Epigenomics wikipedia , lookup
DNA supercoil wikipedia , lookup
Molecular cloning wikipedia , lookup
Microsatellite wikipedia , lookup
Nucleic acid analogue wikipedia , lookup
Genomic library wikipedia , lookup
Extrachromosomal DNA wikipedia , lookup
Primary transcript wikipedia , lookup
Cell-free fetal DNA wikipedia , lookup
Microevolution wikipedia , lookup
Point mutation wikipedia , lookup
Cre-Lox recombination wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Non-coding DNA wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
History of genetic engineering wikipedia , lookup
Helitron (biology) wikipedia , lookup
Deoxyribozyme wikipedia , lookup
Genome editing wikipedia , lookup
No-SCAR (Scarless Cas9 Assisted Recombineering) Genome Editing wikipedia , lookup
CRISPR engineering (DNA, RNA, or DNA/RNA) Service Form No guarantee is made for the number of transgenic mice produced since this depends on a number of factors including: 1) The quality of DNAs/RNAs provided by the investigator (if provided by the investigator) 2) The ability of the guide to target the Cas9 to cut in vivo 3) The chromatin structure/accessibility of the DNA sequence to be targeted (highly variable and unpredictable) Please check the box next to the indicated responsibility as to whether the GTTR (Gene Targeting and Transgenic Resource) is responsible, or the Investigator lab is responsible: Task Responsibility of GTTR Core Responsibility of Investigator Lab To provide DNA vectors and/or RNAs as specified (see the form for specific quantities, volumes and concentrations), to be determined by mutual agreement with staff. To provide a description of the DNA vectors and/or RNAs involved, and a brief description of the experiment. To provide sequence of CRISPR RNAs used, donor DNA molecules to be used for HDR, if any (e.g. DNA oligos or fragments), and the source of Cas for CRISPR injections. (Describe origin of CRISPR backbone and Cas gene being used.) To assure that the DNA and/or RNA fragment(s) will not produce any contagious condition that may be harmful to animals or to humans and that they do not exceed containment requirements greater than those specified by NIH BL-2 standards. To inform the number of transgenic mice obtained after tail DNA analysis by Southern or PCR within 1 month of being notified that tail samples are ready for screening. Recommended number of injection days to request: Because the number of embryos available for injection each day will vary, we guarantee at least 150-300 embryos will be injected per scheduled project. The actual number injected may be more than this, but will not be less or the strain of the mouse chosen. CRISPR Project: Request Information Date: Investigator: Institute: Address: E-Mail: Phone Number: IACUC/animal welfare protocol number: _ Descriptive Name for this CRISPR Project Please provide a brief but clearly identifiable name. (Will appear on cage card as written here): Brief description of desired outcome of project i.e. what is the mouse you want to make? CRISPR-mediated cleavage can result in mutagenesis of both copies of the target gene. Could inactivation of the target gene(s) cause lethality or abnormal phenotypes, either in the heterozygous or homozygous state? If so please explain. For CRISPR project: Please complete this section. Targeted Gene(s) MGI ID: Targeted Gene(s) Name: Targeted Gene(s) Symbol: Please list the names and protospacer sequences of any CRISPR guide RNAs to be injected (alternatively, if the GTTR does the design and production, we will fill out and return back to you): * For the embryonic expression of the CRISPR and Cas9 components, which types of nucleic acids will be injected: either DNA plasmids, or in vitro transcribed RNAs? (Check one) DNA RNA _ Both _ If you answered DNA to the previous question marked by *, complete the following section. If you marked RNA, skip this section. Describe the DNA vector(s) used: Vector size: Method of vector DNA purification: If you answered RNA to question marked by *, complete the following section. If you marked DNA, skip this section. Cas9 RNA: Provided by outside vendor? Yes _ No _ If Yes, list the vendor: If No, please list the source template plasmid, synthesis and purification methods: Cas9 Template: Cas9 Synthesis and Purification methods: Final concentrations of oligo/guide/nuclease will be as follows: Each Injected oligo will be 100ng/ul; Each Guide RNA will be 50ng/ul and Cas9 will be 20ng/ul. Please plan accordingly as they need to be resuspended together at a final injection volume of 50uL/day (at least). Deviations from these concentrations, if requested, should be explained below: For all CRISPR projects: Does this injection also require injection of additional DNA components, such as donor molecules (oligos or DNA fragments) that are intended to edit, recombine with, or insert into the CRISPR genomic target site(s), as via the homology-dependent repair pathway? Yes _ No _ If the answer to the last question is yes, list and describe any DNA oligos or fragments used in combination with CRISPR RNAs for gene editing (provide these DNA sequences in a separate document) (alternatively, if the GTTR does the design and production, we will fill out and return back to you): Do you have any prior evidence that the exact same CRISPR target(s) can generate mutations with efficiency? (E.g. prior injection or transfection data using the same CRISPR). If so please describe the experiment and recorded efficiency: Please describe the methods that will be used to screen and verify any CRISPR-generated mutations/genome editing in the founder animals (e.g. Surveyor assays, direct sequencing, or other) (alternatively, if the GTTR does the design and production, we will fill out and return back to you): Strain of mice desired for injections: _ (B10xC3H hybrid; C57BL/6J; other?) Provide a brief description of the intended use of the engineered mice to be generated: FOR CRISPR PROJECT REQUESTS, Please attach to this form (alternatively, if the GTTR does the design and production, we will fill out and return back to you): 1. Sequences of guide RNAs and any DNA oligos/donor fragments being injected 2. If available, photos of gel analysis of RNAs. 3. Example of PCR demonstrating successful amplification of the wild-type mutation target from mouse genomic DNA. CRISPR-Cas Disclaimers: • CRISPR-Cas-mediated “genome editing” is a rapidly emerging technology. Although the core has demonstrated successful in vivo target cleavage in mouse embryos in a limited number of experiments, not all targets may induce genome editing equally well, and so the GTTR cannot guarantee successful cleavage/editing. It is the responsibility of the investigator to confirm whether mutagenesis and/or genome editing has occurred successfully in the resulting mice. • SgRNA-mediated cleavage has been reported to be prone to off-target mutagenesis. These events have been observed in some CRISPR-modified mice, although not all CRISPR guide RNAs will be highly prone to this problem. The GTTR does not hold responsibility for off-target mutations. • DNA cleavage often occurs at the 1-cell stage, but may occur at the 2-cell stage or later. CRISPRmediated mutagenesis can therefore generate mosaic animals with regards to the proportion of cells that carry specific mutations. On the other hand, more than 2 types of mutations at a single target site can sometimes be observed in tissues from the injected mice. Thus, PCR detection of mutations in liveborn mice does not guarantee germline transmission of particular mutations is efficient or possible (although it typically should be). • CRISPR-Cas-mediated mutagenesis can affect both alleles in a 1-cell embryo. Thus, increased lethality may result from targeting essential genes, reducing yield of liveborn pups and/or correctly targeted pups • Mice will be released/shipped to the investigator only when payment for the project has been made, and when proper animal transport paperwork is completed. Investigator’s signature: ◎ Please submit the completed form to [email protected]. Beijing SBS Genetech Co. Ltd. Fax: +86-10-82784290 Email: [email protected], [email protected] Website: www.sbsbio.com